Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Mitapivat Coated Granules
NCT04565678Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mitapivat in pyruvate kinase deficiency (PKD) (4 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Maximum Observed Concentration Under Fasted Conditions up to 72 hours, Area Under the Plasma Concentration-Time Curve from Time Zero to Last Quantifiable Concentration Under Fasted Conditions up to 72 hours and 2 more. Started Sep 2020; status: completed.
02
Drugs
mitapivat
03
Conditions
pyruvate kinase deficiency (PKD)
Beyond the preview
Go deeper on NCT04565678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04565678.